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Interleukin 6 (IL-6) is a major pro-inflammatory cytokine and dysregulation of IL-6 is relevant to many inflammatory
diseases. Endotoxin induced tolerance of IL-6 is an important mechanism to avoid the excessive immune reaction.
But to date, the molecular mechanisms of endotoxin tolerance of IL-6 remain unclear. Here we reported that IL-6
secretion and microRNA-181b (miR-181b) expression were inversely correlated following LPS stimulation. We also
demonstrated that miR-181b targeting the 3′-UTR of IL-6 transcripts and up-regulation of miR-181b was associated
with NF-kB. We further demonstrated that up-regulation of miR-181b in response to LPS was required for inducing
IL-6 tolerance in macrophage. Our results suggested that the post-transcriptional control mediated by miR-181b
could be involved in fine tuning the critical level of IL-6 expression in endotoxin tolerance.
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The innate immune system is an evolutionarily conserved
defense mechanism against pathogens, which have been de-
tected by the fundamental pattern recognition receptors
(PRRs). Toll like receptors (TLRs) family have emerged as
an important group of PRRs [1]. During bacterial, viral, and
fungal invasion, danger signals are effectively detected by
TLR4 and lead to inflammatory cells activation, pro-
inflammatory cytokines/chemokines production (e.g., TNF-
a, IL-1, IL-6 and COX-2) through the MyD88–dependent
and/or MyD88-independent signaling pathway. And then,
after the burst of pro-inflammatory cytokines, the body de-
veloped a compensatory anti-inflammatory response and
released anti-inflammatory cytokines such as IL-10 and
TGF-β that inhibit the pro-inflammatory immune response
[2]. These inflammatory reactions which induced by LPS
are necessary for neutralizing the expand of gram-negative
bacteria, but it should be tightly regulated in vivo. Uncon-
trolled inflammation leads to extensive tissue damage, sep-
sis syndrome, and even endotoxin shock [3]. The immune
system has developed a defence mechanism including* Correspondence: chmping@126.com; yanmei.ma@gmail.com
†Equal contributors
2Children’s Heart Center, the Second Affiliated Hospital & Yuying Children’s
Hospital, Institute of Cardiovascular Development and Translation Medicine,
Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
1Department of Emergency, Changhai Hospital, Shanghai 200433, China
Full list of author information is available at the end of the article
© 2015 Zhang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.endotoxin tolerance against these uncontrolled inflamma-
tions thus preventing harmful pathologies like sepsis.
IL-6 is one important pro-inflammatory cytokines in
inflammatory response and must be down-regulated in
order to avoid excessive inflammation [4]. LPS tolerance
was reduced in SOCS-1 deficient mice as shown by in-
creasing TNF-α and IL-6 production which compared
with the wild-type mice [5]. Activation of PPAR gamma
by LPS negatively regulates macrophage activation by
decreasing TNF-α, IL-6, IL-1β and NO production [6].
Similarly, ATF3 is reported to down-regulate IL-6 pro-
duction and protect from LPS shock in mice [7]. But to
date, the molecular mechanisms of endotoxin tolerance
of IL-6 remain to be resolved clearly.
MicroRNAs (miRNAs) are one small noncoding RNAs
which regulate gene expression by targeting the 3′-untrans-
lated regions (3′-UTR) of target mRNAs, and have diverse
functional roles in biological processes [8]. The endogen-
ously expressed miRNAs have been identified as important
contributors to many physiological and pathological pro-
cesses including immune tolerance [9]. miRNAs can regu-
late tolerance at many levels of the cell signaling cascade.
The roles such as miR-146a, miR-221, miR-579, miR-125b,
miR-155, let-7e, and miR-98 have been identified in regulat-
ing the TLR4 signaling pathway during the development of
endotoxin tolerance at receptor, signaling pathway, gene
transcription and translational levels [10]. However, itThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Zhang et al. Journal of Inflammation  (2015) 12:18 Page 2 of 9remains unclear whether miRNA mediated regulatory
mechanism is involved in IL-6 production in TLR-
triggered macrophages tolerance.
In the present study, we reported that up-regulation of
miR-181b after LPS exposure partially contributes to
down-regulation of IL-6, which might be an important
regulatory mechanism for controlling pro-inflammatory
immune response and induction of endotoxin tolerance.Methods
Cell culture and tolerance
HEK-293 and RAW264.7 cell lines were obtained from
American Type Culture Collection (Manassas, VA) and cul-
tured in DMEM containing 10% FBS. Cells were maintained
at 37.0°C in a humidified atmosphere with 5% CO2.
RAW264.7 cells were made tolerant by incubation with
100 ng/ml LPS (Sigma-Aldrich, St. Louis, MO). 24 h later,
tolerant cells were washed and resuspended in complete



























Abbreviations: F forward primer, R reverse primer WT wild type, MUT mutant, RT, revLuciferase reporter assays
Luciferase reporter construct was made by cloning hu-
man IL-6 3′-UTR sequence into pMIR-Report construct
(Ambion, Austin, USA). Wild type or mutant IL-6 3′-
UTR fragment (from 84 to 127) was amplified and
cloned into the luciferase reporter via Spe I and Hind III
sites. All the primers were listed in Table 1. Cells plated
in a 96-well plate were co-transfected with 100 nM
single-stranded miRNA inhibitors or negative control
inhibitors, 50 ng of firefly luciferase reporter and 10 ng
of pRL-TK (Promega, USA) using the JetPRIME reagent.
Cells were collected 36 h after last transfection and ana-
lyzed using Dual-Luciferase Reporter Assay System
(Promega).Detection of cytokine production
IL-6 production in the cell supernatants were measured
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Total RNA was extracted with TRIzol (Invitrogen). Puri-
fied mRNA and miRNAs were detected by qRT-PCR
assay using SYBR Green detection chemistry. U6 small
RNA was used as an internal control for normalization
and quantification of miRNA expression. β-actin was
used as an internal control for normalization and quan-
tification of IL-6 expression. All primers were listed in
Table 1.Oligonucleotides transfection
RNA oligos were chemically synthesized and purified by
Genepharma Co. Ltd., (Shanghai, China). The sequence
of miR-181b inhibitor was 2′-O-Me- ACC CAC CGA
CAG CAA UGA AUG UU. The sequence of negative
control inhibitor was 2′-O-Me-UUG UAC UAC ACA
AAA GUA CUG. p65 siRNA was 5′-AAG AAG CAC
AGA UAC CAC CAA dTdT-3′ and 5′-UUG GUG GUA
UCU GUG CUU CUU dTdT-3′. Negative control
siRNA was 5′-AAU UCU CCG AAC GUG UCA
CdTdT-3′ and 5′-GUG ACA CGU UCG GAG AAU
UdTdT-3′. The transfections were performed with
INTERFERin reagent. The final concentration of
miRNA inhibitors was 100 nM. The final concentration
of siRNA was 20 nM.Western blot analysis
Proteins were separated on a 12% SDS-PAGE gel and
transferred onto a nitrocellulose membrane (Bio-Rad,
Hercules, USA). The membrane was blocked with 5%
non-fat milk and incubated with anti-p65 antibody
(Santa Cruz, CA) or anti-β-actin antibody (Sigma, CA,
USA). After being washed extensively, a goat anti-
mouse secondary antibody was added to the system.
The proteins were detected using ECL reagents (Pierce).ChIP assay
ChIP assay was performed as described previously [11].
Antibodies to p65 (Santa Cruz sc-109), and control IgG
(Santa Cruz sc-2027) were used at 5 μg per immunopre-
cipitation. 10 μl sonicated but preimmunoprecipitated
DNA from each sample was used as input control. All
results were normalized to input in each sample. All
primers were listed in Table 1.Statistical analysis
All statistical analyses were carried out using the SPSS
16.0 statistical software package. Data was presented as
the mean ± S.D. Statistical significance was determined
by Student’s t-test, with values of P < 0.05 considered to
be statistically significant.Results
miR-181b and IL-6 are differentially expressed during LPS
induced tolerance in RAW264.7 cells
Previous study has demonstrated that IL-6 protein signifi-
cantly increased after LPS stimulation and then incited
the “cytokine storm” at the onset of severe systemic in-
flammation (SSI), and then, IL-6 protein level rapidly de-
creased and reached background levels by 24 h [12]. This
coincided with the induction of LPS tolerance, as cells
were unable to respond to a second dose of LPS in
RAW264.7 cells (Figure 1A). However, the underlying
mechanism which is involved in TLR-triggered IL-6 toler-
ance remains unclear. In order to investigate potential role
of miRNAs in translational repression of IL-6 in LPS in-
duced tolerance. Two commonly used computational tar-
get prediction algorithms miRanda (http://www.microrna.
org/microrna/home.do) and RNA22 (https://cm.jefferson.
edu/rna22v2/) were used to screen the potential miRNAs
targeting IL-6. As shown in (Figure 1B), four miRNAs (miR-
181a, miR-181b, miR-181c and let-7 g) were predicted by
both of these prediction algorithms to have sequences
complementary to 3′-UTR of IL-6. Then, we investigated
the expression of miR-181a, miR-181b, miR-181c and let-
7 g during LPS induced tolerance in RAW264.7 cells. As
shown in Figure 1C, miR-181a and miR-181b were in-
creased during first LPS stimulation and maintained these
levels during LPS tolerance, while, miR-181c was main-
tained at a relatively low level and the expression of let-7 g
was down-regulated in this process. The most significantly
upregulated miR-181b, which could rescue septic mice by
regulating the NF-κB signaling pathway [13], was selected
for further study.
IL-6 is the direct target of miR-181b
In order to investigate whether miR-181b could target and
regulate the expression of IL-6, we performed the follow-
ing experiments. We found the potential targeting se-
quence for miR-181b is within the 3′-UTR of IL-6 mRNA
from 110 to 118. We first performed luciferase reporter as-
says in HEK-293 cells. We created luciferase reporter plas-
mid with wild type or mutant targeting sequence of IL-6
mRNA (Figure 2A), which were cotransfected with miR-
181b inhibitors or negative control inhibitors into HEK-
293 cells for 48 h, followed by measurement of luciferase
activity in transfected cells. Our results showed that the re-
porter plasmid with wild-type 3′-UTR of IL-6 caused a sig-
nificant increase in luciferase activity in cells transfected
with miR-181b inhibitors, whereas reporter plasmid with
mutant 3′-UTR of IL-6 produced no change in luciferase
activity (Figure 2B). We further performed luciferase re-
porter assays in RAW264.7 cells. As shown in Figure 2C,
miR-181b inhibitors also markedly increased the luciferase
activity in RAW264.7 cells. Then, we explored whether the
endogenous IL-6 in RAW264.7 cells was regulated by
Figure 1 (See legend on next page.)
Zhang et al. Journal of Inflammation  (2015) 12:18 Page 4 of 9
(See figure on previous page.)
Figure 1 miR-181b and IL-6 are differentially expressed during LPS induced tolerance in RAW264.7 cells. (A) RAW264.7 cells were primed
with 100 ng/ml LPS (1st LPS) continuously for 24 h and washed twice with PBS, cells were incubated in fresh complete culture medium for 12 h
with 100 ng/ml LPS (2nd LPS) for 12 h. Levels of total (intracellular and secreted) IL-6 protein were measured by ELISA. (B). miRNAs targeting
3′-UTR of IL-6 were predicted by miRanda and RNA22. miRNAs predicted by both miRanda and RNA22 were tagged by triangle. (C) RAW264.7
cells were treated as in (A). miR-181a, miR-181b, miR-181c and let-7 g were determined by qRT-PCR. Sample data were normalized to U6 mRNA.
The samples were assayed in triplicate. Data represent the mean ± S.D. from at least three independent experiments.
Figure 2 miR-181b directly targets IL-6 gene. (A)miR-181b and its putative binding sequence in the 3′-UTR of IL-6. Mutant sequences were shown in
bold type. (WT: wild type; MUT: mutant type). (B, C) Analysis of luciferase activity. (B) HEK-293 cells and (C) RAW264.7 cells were cotransfected with
miR-181b inhibitors or negative control inhibitors, pRL-TK and firefly luciferase reporter plasmid containing 3′ UTR of IL-6 gene. pRL-TK was cotransfected as
an internal control to correct the differences in both transfection and harvest efficiencies. The firefly luciferase activity of each sample was normalized to
the Renilla luciferase activity. The normalized luciferase activity of negative control inhibitors was set as relative luciferase activity 1 respectively. (D) Effects
of miR-181b inhibitors on the endogenous IL-6 mRNA levels. RAW264.7 cells were cotransfected with miR-181b inhibitors or negative control inhibitors.
24 h after transfection, cells were primed with 100 ng/ml LPS continuously for 6 h and 12 h, and then cells were isolated, the expression of IL-6 was
analyzed by qPCR. (E) Effects of miR-181b inhibitors on the endogenous IL-6 protein levels. 24 h after transfection with the miR-181b inhibitors or negative
control inhibitors, cells were primed with 100 ng/ml LPS continuously for 6 h and 12 h, and then cells were isolated. RAW264.7 cells were analyzed by
ELISA. NC: negative control; I: inhibitors. The data were subjected to Student’s t-test. *p< 0.05, **p< 0.01.
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miR-181b inhibitors or negative control inhibitors, 24 h
later, these cells were stimulated with 100 ng/ml LPS for
6 h and 12 h, IL-6 mRNA and protein levels were exam-
ined by RT-PCR and ELISA, respectively. IL-6 mRNA ex-
pression was not affected by these inhibitors (Figure 2D).
The level of IL-6 protein was consistently and substantially
up-regulated by miR-181b inhibitors (Figure 2E). Taken to-
gether, our results demonstrated that IL-6 was a direct tar-
get of miR-181b in macrophages.
Up-regulation of miR-181b during LPS stimulation in
RAW264.7 cells is associated with NF-kB
The expression of several miRNAs such as miR-155 and
miR-146 has been demonstrated to increased after LPS
treatment in previous studies, which have been a clue in
LPS response and tolerance models [14]. To investigate the
potential mechanism of up-regulation of miR-181b by LPS,
firstly, we analyzed the pri-miR-181b expression in
RAW264.7 cells after LPS stimulation by qRT-PCR. As
shown in Figure 3A, the expression of pri-miR-181b in-
creased during LPS stimulation which was similar to ma-
ture miR-181b. These results suggested that up-regulation
of miR-181b in LPS induced tolerance was regulated at
transcriptional levels. NF-kB was reported to regulate ex-
pression of miR-146a at transcriptional levels [15]. So we
investigate whether up-regulation of miR-181b might be as-
sociated with NF-kB. Knockdown of NF-kB was performed
using one siRNA for p65 gene, which was the main com-
plex of NF-kB [16]. The mRNA and protein expression of
p65 were detected by qRT-PCR and Western blotting, as
shown in Figure. 3B and C, the expression of p65 in
RAW264.7 cells was down-regulated significantly by p65
siRNAs. We also detected the expression of pri-miR-181b
during LPS stimulation after knockdown of NF-kB, the re-
sults showed that up-regulation of pri-miR-181b during
LPS stimulation was suppressed significantly in NF-kB
knockdown cells (Figure 3D). The regions (2500 bp up-
stream of pre-miRNA) were postulated as promoters of
miRNAs to investigate the epigenetic regulation of miRNA
expression [11]. So we chose this region as potential pro-
moter to investigative the p65 binding of miR-181b. ChIP
assays showed that p65 binding activity was up-regulated in
promoter region of miR-181b during LPS stimulation
(Figure 3E, F). Taken together, our results demonstrated
that up-regulation of miR-181b in LPS tolerance was NF-
kB-dependent.
LPS-induced down-regulation of IL-6 during tolerance is
abrogated by miR-181b inhibitors
Considering down-regulation of IL-6 acts as a hallmark
of endotoxin-tolerant macrophages [14], we further
investigated whether LPS-mediated up-regulation of
miR-181b was involved in the induction of LPS-hyporesponsiveness. Recently, a few reports have shown
that epigenetic silencing contributed to the induction of
LPS-hyporesponsiveness [17,18]. When treating macro-
phages with Trichostatin A (TSA), a specific inhibitor of
histone deacetylase (HDAC), the tolerant cells produce
IL-6 again [19]. So we firstly investigated the effect of
TSA on tolerance reversion of IL-6. RAW264.7 cells
were primed with 1st LPS treatment for 24 h, and then
followed by TSA treatment and 2nd LPS treatment. Our
results showed that TSA up-regulated IL-6 expression
in tolerant macrophages (Figure 4A). Nextly, we ex-
plored whether miR-181b also up-regulated the expres-
sion of IL-6 during LPS induced tolerance. RAW264.7
cells were primed with 100 ng/ml LPS for 24 h, followed
by transfection with miR-181b inhibitors, and then
followed by secondary LPS challenge. Interestingly,
comparing with the cells transfected with negative con-
trol inhibitors, RAW264.7 cells transfected with miR-
181b inhibitors produced significantly higher levels of
IL-6 in response to secondary LPS challenge as shown
in Figure 4B, C, which was similar to TSA treatment.
These results demonstrated that LPS-mediated up-
regulation of miR-181b was, at least in part, involved in
the induction of IL-6 tolerance in RAW264.7 cells.
Discussion
In this study, we detected a significant increase of miR-
181b expression in RAW264.7 cells following LPS stimula-
tion, and up-regulation of miR-181b was associated with
NF-kB. We also demonstrated that miR-181b targeted the
3′-UTR of IL-6 and down-regulated expression of IL-6 at
protein levels. Moreover, up-regulation of miR-181b in re-
sponse to LPS may be required for inducing IL-6 tolerance
in macrophages.
IL-6 is secreted by macrophages and T cells to stimu-
late immune response during infection or trauma [20].
IL-6 is one of the most important inflammatory factors
in fever and the acute phase response. The fine tuning
of IL-6 expression is crucial since dysregulation of IL-6
has been attributed to many diseases such as athero-
sclerosis [21], systemic lupus erythematosus [22], Behçet
′s disease [23], diabetes [24], multiple myeloma [25], de-
pression [26], Alzheimer′s Disease [27], prostate cancer
[28] and rheumatoid arthritis [29]. However, the mech-
anism underlying the fine tuning of IL-6 expression es-
pecially in infection induced tolerance remains unclear.
Herein, we provide a new molecular mechanism to be
responsible for IL-6 tolerance in macrophage after LPS
stimulation. We found that miR-181b expression levels
and IL-6 secretion were inversely correlated after LPS
stimulation. We further confirmed that IL-6 3′-UTR
contained one miR-181b binding site and LPS induced
endotoxin tolerance due to the down-regulation of
IL-6 production which was induced by miR-181b
Figure 3 Up-regulation of miR-181b in LPS tolerance is NF-kB-dependent. (A) RAW264.7 cells were primed with 100 ng/ml LPS continuously for
12 h and 24 h. pri-miR-181b were determined by qRT-PCR. Sample data were normalized to β-actin mRNA. (B, C) qRT-PCR and western blots of p65 in
RAW264.7 cells after p65 siRNA or negative control siRNA transfection. β-actin was used as an internal control. (D) RAW264.7 cells were transfected with
p65 siRNA or negative control siRNA, 24 h later, cells were primed with 100 ng/ml LPS continuously for 12 h and 24 h. pri-miR-181b were determined
by qRT-PCR. Sample data were normalized to β-actin mRNA. (E) One set of primers was used in the qPCR analysis to span the potential promoter
region of miR-181b. (F) RAW264.7 cells were primed with 100 ng/ml LPS continuously for 24 h. qPCR analysis of p65 binding in the promoter region of
miR-181b by ChIP assay. NC: negative control. The data were subjected to Student’s t-test. *p < 0.05, **p < 0.01.
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posttranscriptional control could be involved in fine tuning
the critical level of IL-6 expression in endotoxin tolerance.
Our results confirmed, in the course of LPS induced toler-
ance, IL-6 was regulated not only by epigenetic modifica-
tion at the transcriptional level but also by miRNAs at thepost-transcriptional level. Our results were similar to the
previous findings in TNF-α [12].
miR-181b belongs to the miR-181 family including
four members miR-181a, miR-181b, miR-181c, and miR-
181d. The biological functions of miR-181b were widely
investigated. miR-181b was defined as a regulator of the B
Figure 4 miR-181b inhibitors abrogates LPS-induced IL-6 tolerance. (A) Effects of TSA on the endogenous IL-6 protein levels during LPS
tolerance. RAW264.7 cells were primed with 100 ng/ml LPS continuously for 24 h and washed twice with PBS, then cells were primed with 1 μM
TSA and 100 ng/ml LPS. Another 6 h and 12 h later, IL-6 were analyzed by ELISA. cells were primed with 100 ng/ml LPS continuously for 24 h
and washed twice with PBS, then cells were transfected with miR-181b inhibitors and primed with 100 ng/ml LPS. 6 h and 12 h later, miR-181b
were analyzed by qRT-PCR (B) and IL-6 were analyzed by ELISA (C). NC: negative control; I: inhibitors. The data were subjected to Student’s t-test.
**p < 0.01, ***p < 0.001. (B, Ccp Effects of miR-181b inhibitors on the endogenous IL-6 protein levels during LPS tolerance. RAW264.7.
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strict the activity of activation-induced cytidine deaminase
[30]. Altered expression levels of miR-181b have been de-
tected in multiple tumors and leukemia/lymphoma [31-35].
Sun et. al identified patients with sepsis having reduced
circulating plasma levels for miR-181b compared with
control patients without sepsis and identified miR-181b as a
cytokine-responsive miRNA which regulates the endothelial
response to inflammation by regulating the NF-κB signaling
pathway [13]. In our study, we identified miR-181b as
a endotoxin-responsive miRNA with a NF-κB-dependent
manner during LPS induced IL-6 tolerance in macrophages.
These findings coupled with the improved survival observed
in miR-181b “rescue” studies in septic mice suggest that
therapies directed at restoring miR-181b expression may
ameliorate this acute inflammatory process [13]. miR-181
family including miR-181a, miR-181b, miR-181c and miR-
181d have the similar sequence. Whether other miR-181 s
have the similar function like miR-181b during LPS induced
IL-6 tolerance remains to be investigated.
Conclusions
Based on our results, we showed that macrophages were
stimulated by LPS to up-regulate the expression of miR-
181b, and this is related to the immune tolerance of IL-6.
miR-181b down- regulated the expression of IL-6, thus to
avoid the excessive immune response which induced byLPS. We think that we find a target to break the immune
tolerance of IL-6 and a new way to control the clinical in-
fectious disease.
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